DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Non-small Cell Lung Carcinoma
Interventions: DRUG: Trastuzumab deruxtecan (DS-8201a)|DRUG: Trastuzumab deruxtecan (DS-8201a)|DRUG: Pembrolizumab
Sponsor: Daiichi Sankyo
Collaborators: AstraZeneca UK Limited|Merck Sharp & Dohme LLC